CNS Drugs

, Volume 20, Issue 11, pp 879–885 | Cite as

Cytomegalovirus and Schizophrenia

  • E. Fuller Torrey
  • Markus F. Leweke
  • Markus J. Schwarz
  • Norbert Mueller
  • Silke Bachmann
  • Johannes Schroeder
  • Faith Dickerson
  • Robert H. Yolken
Current Opinion

Abstract

Several lines of evidence suggest that cytomegalovirus (CMV) may play an aetiological role in schizophrenia. Epidemiologically, both have a worldwide distribution and an increased prevalence in lower socioeconomic groups. Studies have reported that some patients experiencing initial episodes of schizophrenia have increased levels of IgG antibodies against CMV, but not other herpes viruses, in their sera and CSF. Treatment with antipsychotic medications may result in a decrease in CMV antibodies, while treatment with anti-herpes virus and anti-inflammatory medications may reduce symptoms in some individuals with schizophrenia. There is also some overlap in the genes that are thought to operate in CMV infections and schizophrenia.

The strongest argument against the role of CMV in schizophrenia is the absence of the traditional CMV neuropathological changes in the brains of individuals with schizophrenia; however, neuropathological studies of CMV have mostly been conducted in immune-compromised individuals.

Further studies on CMV and schizophrenia are needed and may lead to improved treatments for schizophrenia.

Keywords

Schizophrenia Celecoxib Varicella Zoster Virus Herpes Virus Chronic Schizophrenia 

Notes

Acknowledgements

Financial support for this study was provided by the Stanley Medical Research Institute. None of the authors have any conflicts of interest that are relevant to the contents of this review.

References

  1. 1.
    Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 2002 Dec; 58(2–3): 101–15PubMedCrossRefGoogle Scholar
  2. 2.
    Torrey EF, Miller J, Rawlings R, et al. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997 Nov; 28(1): 1–38PubMedCrossRefGoogle Scholar
  3. 3.
    Mortensen PB, Pedersen CB, Westergaard T, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med 1999 Feb; 340(8): 603–8PubMedCrossRefGoogle Scholar
  4. 4.
    Harrison G, Gunnell D, Glazebrook C, et al. Association between schizophrenia and social inequality at birth: case-control study. Br J Psychiatry 2001 Oct; 179: 346–50PubMedCrossRefGoogle Scholar
  5. 5.
    Hendrick I. Encephalitis lethargica and the interpretation of mental disease. Am J Psychiatry 1928; 7: 989–1014Google Scholar
  6. 6.
    Goodall E. The exciting cause of certain states of disease, at present classified under “schizophrenia” by psychiatrists, may be infection. J Ment Sci 1932; 78: 746–55Google Scholar
  7. 7.
    Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis 2003 Nov; 9(11): 1375–80PubMedCrossRefGoogle Scholar
  8. 8.
    Yolken RH, Bachmann S, Rouslanova I, et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis 2001 Mar; 32(5): 842–4PubMedCrossRefGoogle Scholar
  9. 9.
    Karlsson H, Bachmann S, Schröder J, et al. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A 2001 Apr; 98(8): 4634–9PubMedCrossRefGoogle Scholar
  10. 10.
    Hart DJ, Heath RG, Sautter Jr FJ, et al, editor. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biol Psychiatry 1999 Mar; 45(6): 704–14PubMedCrossRefGoogle Scholar
  11. 11.
    Dickerson FB, Boronow JJ, Stallings C, et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003 May; 60(5): 466–72PubMedCrossRefGoogle Scholar
  12. 12.
    Buka SL, Tsuang MT, Torrey EF, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001 Nov; 58(11): 1032–7PubMedCrossRefGoogle Scholar
  13. 13.
    Torrey EF, Yolken RH, Winfrey CJ. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science 1982 May; 216(4548): 892–3PubMedCrossRefGoogle Scholar
  14. 14.
    Dauncey K, Giggs J, Baker K, et al. Schizophrenia in Nottingham: lifelong residential mobility of a cohort. Br J Psychiatr 1993; 163: 613–9CrossRefGoogle Scholar
  15. 15.
    Griffiths PD, McLaughlin JE. Cytomegalovirus. In: Scheid WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. New York: Lippincott, Williams & Wilkins, 2004: 159–173Google Scholar
  16. 16.
    Scheid WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. New York: Lippincott, Williams & Wilkins, 2004Google Scholar
  17. 17.
    Hanshaw JB. Cytomegalovirus. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. Philadelphia (PA): Saunders, 1976: 127Google Scholar
  18. 18.
    Torrey EF, Peterson MR. Schizophrenia and the limbic system. Lancet 1974 Oct; II(7886): 942–6CrossRefGoogle Scholar
  19. 19.
    Arribas JR, Storch GA, Clifford DB, et al. Cytomegalovirus encephalitis. Ann Intern Med 1996 Oct; 125(7): 577–87PubMedGoogle Scholar
  20. 20.
    Torrey EF. Functional psychoses and viral encephalitis. Integr Psychiatry 1986; 4: 224–36Google Scholar
  21. 21.
    Rothschild DM, O’Grady M, Wecker L. Neonatal cytomegalovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia. J Neurosci Res 1999 Aug; 57(4): 429–34PubMedCrossRefGoogle Scholar
  22. 22.
    Dickerson F, Kirkpatrick B, Boronow J, et al. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 2006; 32(2): 396–400PubMedCrossRefGoogle Scholar
  23. 23.
    Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995 Jan; 8(1): 131–45PubMedGoogle Scholar
  24. 24.
    Srikanth S, Ravi V, Poornima KS, et al. Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry 1994 Oct; 36(8): 517–21PubMedCrossRefGoogle Scholar
  25. 25.
    Leweke FM, Gerth CW, Koethe D, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004 Feb; 254(1): 4–8PubMedCrossRefGoogle Scholar
  26. 26.
    Albrecht P, Torrey EF, Boone E, et al. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 1980 Oct; II(8198): 769–72CrossRefGoogle Scholar
  27. 27.
    Gotlieb-Stematsky T, Zonis J, Arlazoroff A, et al. Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients. Arch Virol 1981; 67(4): 333–9PubMedCrossRefGoogle Scholar
  28. 28.
    Rimón R, Ahokas A, Palo J. Serum and cerebrospinal fluid antibodies to cytomegalovirus in schizophrenia. Acta Psychiatr Scand 1986 Jun; 73(6): 642–4PubMedCrossRefGoogle Scholar
  29. 29.
    Shrikhande S, Hirsch SR, Coleman JC, et al. Cytomegalovirus and schizophrenia: a test of a viral hypothesis. Br J Psychiatry 1985 May; 146: 503–6PubMedCrossRefGoogle Scholar
  30. 30.
    King DJ, Cooper SJ, Earle JAP, et al. Serum and CSF antibody titres to seven common viruses in schizophrenic patients. Br J Psychiatry 1985 Aug; 147: 145–9PubMedCrossRefGoogle Scholar
  31. 31.
    Kaufmann CA, Weinberger DR, Yolken RH, et al. Viruses and schizophrenia. Lancet 1983 (Nov); II(8359): 1136–7CrossRefGoogle Scholar
  32. 32.
    van Kammen DP, Mann L, Scheinin M, et al. Spinal fluid monoamine metabolites and anti-cytomegalovirus antibodies and brain scan evaluation in schizophrenia. Psychopharm Bull 1984 Summer; 20(3): 519–22Google Scholar
  33. 33.
    Moises HW, Rüger R, Reynolds GP, et al. Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. Eur Arch Psychiatry Neurol Sci 1988; 238(2): 110–3PubMedGoogle Scholar
  34. 34.
    C, Torrey EF, Yolken RH. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr Res 2003 Mar; 60(1): 65–9Google Scholar
  35. 35.
    Dickerson FB, Boronow JJ, Stallings CR, et al. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003 Dec; 160(12): 2234–6PubMedCrossRefGoogle Scholar
  36. 36.
    Mueller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002 Jun; 159(6): 1029–34CrossRefGoogle Scholar
  37. 37.
    Martelius TJ, Wolff H, Bruggeman CA, et al. Induction of cyclo-oxygenase-2 by acute liver allograft rejection and cytomegalovirus infection in the rat. Transpl Int 2002 Dec; 15(12): 610–4PubMedCrossRefGoogle Scholar
  38. 38.
    Zhu H, Cong JP, Yu D, et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 2002 Mar; 99(6): 3932–7PubMedCrossRefGoogle Scholar
  39. 39.
    Hurme M, Helminen M. Resistance to human cytomegalovirus infection may be influenced by genetic polymorphisms of the tumour necrosis factor-alpha and interleukin-1 receptor antagonist genes. Scand J Infect Dis 1998; 30(5): 447–9PubMedCrossRefGoogle Scholar
  40. 40.
    Schwab SG, Mondabon S, Knapp M, et al. Association of tumor necrosis factor alpha gene-G308A polymorphism with schizophrenia. Schizophr Res 2003 Dec; 65(1): 19–25PubMedCrossRefGoogle Scholar
  41. 41.
    Boin F, Zanardini R, Pioli R, et al. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001 Jan; 6(1): 79–82PubMedCrossRefGoogle Scholar
  42. 42.
    Riedel M, Krönig H, Schwarz MJ. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002 Oct; 252: 232–4PubMedCrossRefGoogle Scholar
  43. 43.
    Hurme M, Haanpaa M, Nurmikko T, et al. IL-10 gene polymorphism and herpesvirus infections. J Med Virol 2003; 70Suppl. 1: S48–50PubMedCrossRefGoogle Scholar
  44. 44.
    Chiavetto LB, Boin F, Zanardini R, et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 2002 Mar; 51(6): 480–4CrossRefGoogle Scholar
  45. 45.
    Kim JJ, Dayal M, Bacanu S, et al. Exposure to cytomegalovirus and polymorphisms in two genes on chromosome 6p21-23 as joint risk factors for schizophrenia [abstract]. Am J Med Genetics B Neuropsychiatr Genet 2004 Sept; 130B(1): 19Google Scholar
  46. 46.
    Craighead JE. Cytomegalovirus. In: Pathology and pathogenesis of human viral disease. San Diego (CA): Academic Press, 2000: 87–115Google Scholar
  47. 47.
    Bailey OT, Wolf A, Schneck SA, et al. Iatrogenic modification of tissue responses to infectious agents in the central nervous system. Res Publ Assoc Res Nerv Ment Dis 1968; 44: 445–62PubMedGoogle Scholar
  48. 48.
    Dorfman LJ. Cytomegalovirus encephalitis in adults. Neurology 1973 Feb; 23(2): 136–44PubMedCrossRefGoogle Scholar
  49. 49.
    Reuter JD, Gomez DL, Wilson JH, et al. Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol 2004 Feb; 78(3): 1473–87PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • E. Fuller Torrey
    • 1
  • Markus F. Leweke
    • 2
  • Markus J. Schwarz
    • 3
  • Norbert Mueller
    • 3
  • Silke Bachmann
    • 4
  • Johannes Schroeder
    • 5
  • Faith Dickerson
    • 6
  • Robert H. Yolken
    • 7
  1. 1.The Stanley Medical Research Institute and Uniformed Services University of the Health SciencesBethesdaUSA
  2. 2.Department of Psychiatry and PsychotherapyUniversity of CologneCologneGermany
  3. 3.Laboratory of NeurochemistryPsychiatric Hospital, University of MunichMunichGermany
  4. 4.Department of Psychiatry and PsychotherapyUniversity of HalleHalleGermany
  5. 5.Department of PsychiatryUniversity of HeidelbergHeidelbergGermany
  6. 6.Sheppard Pratt Health SystemsBaltimoreUSA
  7. 7.Stanley Laboratory of Developmental NeurovirologyJohns Hopkins University Medical CenterBaltimoreUSA

Personalised recommendations